Discovery of novel phenyl triazole analogs as TRK/ALK dual inhibitors with prospective antitumor effects

Cao, Zhi; Zhang, Jiahao; Guo, Mengrao; Shao, Bin; Wei, Xiujian; Li, Sen; Wang, Peng; Zhai, Xin

doi:10.1016/j.bioorg.2023.106563

Cited by 2 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phase 1/2 clinical trial (NCT05384626) will evaluate doselimiting toxicities, dosage, and ORR in ALK-positive advanced/ metastatic NSCLC or other solid tumors (Inc, 2022). Furthermore, recent studies report several novel compounds/agents capable of inhibiting ALK (Wang et al, 2022;Cao et al, 2023;Fan et al, 2023).…”

Section: Novel Anaplastic Lymphoma Kinase Inhibitorsmentioning

confidence: 99%

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Kiełbowski,

Żychowska,

Becht

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with proliferation and survival. To date, several agents that target and inhibit ALK have been developed. The most studied ALK-positive disease is non-small cell lung cancer, and three generations of ALK tyrosine kinase inhibitors (TKIs) have been approved for the treatment of metastatic disease. Nevertheless, the use of ALK-TKIs is associated with acquired resistance (resistance mutations, bypass signaling), which leads to disease progression and may require a substitution or introduction of other treatment agents. Understanding of the complex nature and network of resistance mutations may allow to introduce sequential and targeted therapies. In this review, we aim to summarize the efficacy and safety profile of ALK inhibitors, describe off-target anticancer effects, and discuss resistance mechanisms in the context of personalized oncology.

show abstract

Section: Novel Anaplastic Lymphoma Kinase Inhibitorsmentioning

confidence: 99%